Simona Scartoni

457 total citations
14 papers, 101 citations indexed

About

Simona Scartoni is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Simona Scartoni has authored 14 papers receiving a total of 101 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Gastroenterology. Recurrent topics in Simona Scartoni's work include Advanced Breast Cancer Therapies (5 papers), Gastrointestinal motility and disorders (3 papers) and HER2/EGFR in Cancer Research (3 papers). Simona Scartoni is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Gastrointestinal motility and disorders (3 papers) and HER2/EGFR in Cancer Research (3 papers). Simona Scartoni collaborates with scholars based in Italy, United States and Belgium. Simona Scartoni's co-authors include Angela Capriati, Jan Tack, Carlo Alberto Maggi, Giuseppe Tonini, Monica Binaschi, Aditya Bardia, José Á. García-Sáenz, Philippe Aftimos, François‐Clément Bidard and Patrick Neven and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Simona Scartoni

11 papers receiving 99 citations

Peers

Countries citing papers authored by Simona Scartoni

Since Specialization

Citations

This map shows the geographic impact of Simona Scartoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simona Scartoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simona Scartoni more than expected).

Fields of papers citing papers by Simona Scartoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simona Scartoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simona Scartoni. The network helps show where Simona Scartoni may publish in the future.

Co-authorship network of co-authors of Simona Scartoni

This figure shows the co-authorship network connecting the top 25 collaborators of Simona Scartoni. A scholar is included among the top collaborators of Simona Scartoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simona Scartoni. Simona Scartoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. 2025 ·Journal of Clinical Oncology ·(unknown), Virginia Kaklamani, Joyce O’Shaughnessy, Peter Schmid, J. Thaddeus Beck, Michelino De Laurentiis, Giuseppe Curigliano, Hope S. Rugo, Carlos H. Bárcenas, William J. Gradishar, (unknown), David Cameron, Giuseppe Tonini, Simona Scartoni, Jennifer A. Crozier, Leonardo Nicacio, (unknown), Sara M. Tolaney	0
2	Abstract P1-01-25: Elacestrant vs SOC in ER+, HER2- advanced or metastatic breast cancer (mBC) with ESR1-mutated tumors: ESR1 allelic frequencies and clinical activity from the phase 3 EMERALD trial 2025 ·Clinical Cancer Research ·Aditya Bardia, Javier Cortés, (unknown), (unknown), José Á. García-Sáenz, Janice Lu, Giulia Tonini, Simona Scartoni, (unknown), Alessio Fiascarelli, Alessandro Bressan, Monica Binaschi, (unknown), Virginia Kaklamani	0
3	Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups 2024 ·Clinical Cancer Research ·Aditya Bardia, Javier Cortés, François‐Clément Bidard, Patrick Neven, José Á. García-Sáenz, Philippe Aftimos, Joyce O’Shaughnessy, Janice Lu, (unknown), Simona Scartoni, (unknown), Monica Binaschi, (unknown), Virginia Kaklamani	33
4	Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET). 2023 ·Journal of Clinical Oncology ·Virginia Kaklamani, François‐Clément Bidard, Patrick Neven, Alberto J. Montero, Marie‐Ange Mouret‐Reynier, Joohyuk Sohn, Donatienne Taylor, Frédéric Forget, Kathleen Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Simon Waters, José Á. García-Sáenz, Philippe Aftimos, Javier Cortés, Simona Scartoni, Nassir Habboubi, Aditya Bardia	4
5	Abstract OT2-01-03: ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC) 2023 ·Cancer Research ·Hope Rugo, Aditya Bardia, Javier Cortés, Giuseppe Curigliano, Erika Hamilton, Sara A. Hurvitz, Sibylle Loibl, Simona Scartoni, Tarek Sahmoud, Krzysztof Grzegorzewski, Nassir Habboubi, Joyce O’Shaughnessy	10
6	First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia 2019 ·Blood ·Scott R. Solomon, Aziz Nazha, Stephen A. Strickland, Roland B. Walter, (unknown), (unknown), (unknown), (unknown), Simona Scartoni, (unknown), Monica Binaschi, (unknown), (unknown), Krzysztof Brzózka, Angela Capriati, Andrea Pellacani, Farhad Ravandi	1
7	The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS 2016 ·Gut ·Jan Tack, (unknown), Giuseppe Tonini, Simona Scartoni, Angela Capriati, Carlo Alberto Maggi	37
8	Su1161 The Response Rate After Single and Repeated Doses of Nepadutant As Symptomatic Treatment of Infant Colic: the NO-CRY Phase II Clinical Trial 2015 ·Gastroenterology ·Sibylle Koletzko, (unknown), Anna Shcherbina, A.N. Galustyan, (unknown), (unknown), (unknown), Simona Scartoni, Francesca Masciopinto, (unknown), Angela Capriati, Carlo Alberto Maggi	1
9	Su1160 A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy of 7 Days of Orally Administered Nepadutant in Infants With Colic - the NO-CRY Study 2015 ·Gastroenterology ·Sibylle Koletzko, (unknown), Anna Shcherbina, A.N. Galustyan, (unknown), (unknown), (unknown), Simona Scartoni, (unknown), Francesca Masciopinto, (unknown), (unknown), Angela Capriati, Carlo Alberto Maggi	2
10	Febuxostat Pharmacokinetic/Pharmacodynamic Bridging from Adults to Pediatrics for Effective Prophylaxis of Tumor Lysis Syndrome: From Florence to Floret Study 2015 ·Blood ·Michele Spina, (unknown), (unknown), (unknown), (unknown), Mariagiuseppa Matera, (unknown), (unknown), (unknown), Simona Scartoni, Angela Capriati, Cecilia Simonelli, Franco Locatelli	0
11	"ARMY": First-in-human study of the humanized, defucosylated monoclonal antibody (mAb) MEN1112/OBT357 targeting CD157 antigen, in relapsed or refractory (R/R) acute myeloid leukemia (AML). 2015 ·Journal of Clinical Oncology ·Adriano Venditti, Dimitri Breems, Violaine Havelange, Giovanni Martinelli, (unknown), Monica Binaschi, Attilio Crea, Eugen Leo, Carlo Alberto Maggi, Stefano Manzini, Mariagiuseppa Matera, (unknown), Cristina Rossi, Simona Scartoni, (unknown), Giuseppe Tonini, Keith E. Wilson, Angela Capriati, Cecilia Simonelli	3
12	Pharmacokinetics of Dexketoprofen and tramadol given in combination: an open-label, randomized, 3-period crossover study in Healthy subjects 2015 ·Clinical Therapeutics ·P. Mazzei, Stefano Milleri, (unknown), (unknown), (unknown), Attilio Crea, Francesca Masciopinto, (unknown), Simona Scartoni, Marco Bertolotti, Angela Capriati, C.A. Maggi	3
13	Mo1056 Weekly Assessment of Satisfactory Relief vs. Quantitative Daily Assessment of Signs and Symptoms in IBS: Do They Provide Comparable Data? the IRIS-2 Study Experience With Ibodutant in IBS-D 2013 ·Gastroenterology ·Jan Tack, (unknown), Simona Scartoni, (unknown), Franca Ligas, Angela Capriati, Carlo Alberto Maggi	3
14	Effect of metformin on recurrence-free survival and overall survival in diabetic patients affected by advanced ovarian cancer. 2013 ·Journal of Clinical Oncology ·Cecilia Simonelli, (unknown), Paul Sabbatini, Jonathan S. Berek, Jacobus Pfisterer, Monica Binaschi, (unknown), Carlo Alberto Maggi, Simona Scartoni, Angela Capriati	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact